- Home
- ZTEK vs CCCC Comparison
ZTEK vs CCCC Comparison
Compare ZTEK & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- CCCC
- Stock Information
- Founded
- ZTEK 2008
- CCCC 2015
- Country
- ZTEK Canada
- CCCC United States
- Employees
- ZTEK N/A
- CCCC N/A
- Industry
- ZTEK Major Chemicals
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- ZTEK Industrials
- CCCC Health Care
- Exchange
- ZTEK Nasdaq
- CCCC Nasdaq
- Market Cap
- ZTEK 103.3M
- CCCC 115.0M
- IPO Year
- ZTEK N/A
- CCCC 2020
- Fundamental
- Price
- ZTEK $1.65
- CCCC $1.52
- Analyst Decision
- ZTEK
- CCCC Buy
- Analyst Count
- ZTEK 0
- CCCC 4
- Target Price
- ZTEK N/A
- CCCC $12.50
- AVG Volume (30 Days)
- ZTEK 77.4K
- CCCC 1.3M
- Earning Date
- ZTEK 06-26-2025
- CCCC 05-07-2025
- Dividend Yield
- ZTEK N/A
- CCCC N/A
- EPS Growth
- ZTEK N/A
- CCCC N/A
- EPS
- ZTEK N/A
- CCCC N/A
- Revenue
- ZTEK $44,936.00
- CCCC $39,783,000.00
- Revenue This Year
- ZTEK N/A
- CCCC N/A
- Revenue Next Year
- ZTEK N/A
- CCCC $36.31
- P/E Ratio
- ZTEK N/A
- CCCC N/A
- Revenue Growth
- ZTEK 92.38
- CCCC 98.56
- 52 Week Low
- ZTEK $0.50
- CCCC $1.09
- 52 Week High
- ZTEK $1.31
- CCCC $7.66
- Technical
- Relative Strength Index (RSI)
- ZTEK 65.29
- CCCC 50.01
- Support Level
- ZTEK $1.51
- CCCC $1.42
- Resistance Level
- ZTEK $1.83
- CCCC $1.69
- Average True Range (ATR)
- ZTEK 0.18
- CCCC 0.16
- MACD
- ZTEK 0.02
- CCCC 0.03
- Stochastic Oscillator
- ZTEK 79.13
- CCCC 56.82
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.